Metformin lowers moderate (nondiabetic) fasting hyperglycaemia in individuals at risk for type 2 diabetes without causing hypoglycaemia. In addition, it has demonstrated favourable action on several cardiovascular risk factors that are often present in these individuals: it favours the maintenance of diet-induced weight loss and its associated improvement in fibrinolysis; and it lowers plasma concentrations of fasting insulin, total and low density lipoprotein-cholesterol, free fatty acids, and of two markers of endothelial damage − tissue plasminogen activator antigen and von Willebrand factor. These effects together with the good tolerability profile of the drug position metformin as a first-line agent for the prevention of type 2 diabetes. The prevention of type 2 (non-insulin-dependent) diabetes mellitus entails the attenuation of diabetic hyperglycaemia and its associated complications. There is epidemiological [1] and therapeutic [2] evidence that the prevention of diabetic hyperglycaemia in turn prevents the development of microangiopathy. The situation is quite different for macrovascular complications, however.
The prevention of type 2 (non-insulin-dependent) diabetes mellitus entails the attenuation of diabetic hyperglycaemia and its associated complications. There is epidemiological [1] and therapeutic [2] evidence that the prevention of diabetic hyperglycaemia in turn prevents the development of microangiopathy. The situation is quite different for macrovascular complications, however.
Patients with type 2 diabetes often present with a cluster of cardiovascular risk factors (visceral obesity, hypertension, high triglyceride and low high density lipoprotein-cholesterol levels, and hypofibrinolysis), all of which form the insulin resistance or metabolic syndrome and potentially contribute to increased cardiovascular risk. In addition, the insulin resistance syndrome precedes diabetic hyperglycaemia and cannot be prevented or treated solely by the lowering of blood glucose levels. Metformin, a well known and well tolerated antihyperglycaemic drug with effects on several metabolic anomalies associated with the insulin resistance syndrome, is a good candidate drug for the prevention of type 2 diabetes.
Prevention of Diabetic Hyperglycaemia
Even in nondiabetic hyperglycaemia, metformin reduces fasting blood glucose levels without causing hypoglycaemia. In the BIGPRO (Biguanides and the Prevention of the Risk of Obesity) 1 trial in 324 nondiabetic men and women with visceral obesity who were treated for 1 year with metformin 850mg twice daily or placebo in addition to lifestyle recommendations, fasting blood glucose levels decreased significantly in patients who were glucose intolerant at study entry but not in those who were normoglycaemic. [3] Any agent used for the prevention of type 2 diabetes must maintain a long term glucose-lowering effect. This has been shown clearly in the United Kingdom Prospective Diabetes Study (UKPDS). Overall, after an initial decrease, fasting blood glucose levels returned to their baseline values after 4 to 6 years, and subsequently increased steadily regardless of drug treatment. [4] The UKPDS showed that, once blood glucose levels have reached 8 mmol/L, the average level at inclusion, diabetes progresses because of deteriorating β-cell function. It is possible, however, that initial treatment at a lower fasting blood glucose level will lead to a greater level of β-cell protection.
There are 2 preliminary reports of the effect of metformin on the incidence of type 2 diabetes in individuals with moderate hyperglycaemia. In a randomised trial in 70 individuals with impaired glucose tolerance, a 21% conversion rate was noted in the placebo group versus 3% in the metformintreated (250mg 3 times daily) group over 1 year (p < 0.05). [5] In a subgroup of individuals with moderate fasting hyperglycaemia (6 to 7.7 mmol/L) in the UKPDS, metformin treatment (at a maximum dosage of 2550 mg/day) was reported to confer a 50% reduction relative to diet only, in the risk of progression to diabetic hyperglycaemia (≥7.8 mmol/L) over 6 years in obese patients (p < 0.004). [6] These results do not allow firm conclusions to be drawn, however.
Metformin has been selected for one of the intervention arms in the US Diabetes Prevention Program, an ongoing 3-to 6-year clinical trial to study the prevention of type 2 diabetes in individuals with impaired glucose tolerance. This trial will provide a more accurate assessment of the protective effect of metformin treatment and may address the question of the effect of early treatment of blood glucose elevation on the rate of degradation of β-cell function.
Prevention of Cardiovascular Disease in Individuals at Risk of Type 2 Diabetes
Recent epidemiological studies in patients with diabetes have confirmed that chronic hyperglycaemia is an independent risk factor for cardiovascular disease. [7, 8] Because of its antihyperglycaemic effect, metformin may therefore have a potential effect on the prevalence of cardiovascular disease (as may other antihyperglycaemic agents). However, the insulin resistance syndrome which precedes the development of hyperglycaemia may be the main cause of high cardiovascular risk in individuals with type 2 diabetes. [9] Metformin is an insulin sensitiser [10] and has shown beneficial effects on several cardiovascular risk factors in individuals at risk of type 2 diabetes.
In the BIGPRO 1 trial in individuals with visceral obesity, [3, 11] those treated with metformin showed greater weight loss (p < 0.06), a greater decrease in fasting insulin levels (p < 0.06) and a smaller increase in low density lipoprotein (LDL)-cholesterol concentrations (p < 0.07) than those who received placebo. In this trial, the effect of metformin was most notable on levels of 2 markers of endothelial damage, tissue plasminogen activator (t-PA) antigen (p < 0.02) and von Willebrand factor (p < 0.02). [11] Bodyweight loss was associated with a significant decrease in plasminogen activator inhibitor-1 (PAI-1) activity. Metformin by itself did not improve fibrinolysis in addition to what could be expected from its weight loss-promoting effect, [10] and did not show any significant effect on fasting triglyceride levels or blood pressure. The results of BIGPRO 1 were confirmed by the BIGPRO 1.2 trial in men with visceral obesity, hypertension and high fasting triglyceride levels (unpublished data). A subgroup analysis of the two BIGPRO trials suggests that metformin may lower blood pressure only in hyperglycaemic individuals (unpublished data). Common to all conditions Decrease in total cholesterol, LDL-cholesterol, free fatty acids, t-PA ag and insulin levels LDL = low density lipoprotein; PAI-1 = plasminogen activator inhibitor-1; t-PA ag = tissue plasminogen activator antigen.
In 3 recent placebo-controlled clinical trials in nondiabetic patients with hypertension, [12] [13] [14] metformin significantly decreased fasting insulin or C-peptide levels, [12] [13] [14] total cholesterol, LDLcholesterol or apolipoprotein B levels, [12, 13] and fasting free fatty acid [13] and t-PA antigen [13] levels. Metformin had a significant effect on blood pressure and fasting triglyceride levels in one study only. [12] In combined hyperlipidaemia, metformin significantly reduced total and LDL-cholesterol but not fasting triglyceride levels. [15] The effect of metformin on LDL-cholesterol levels was found to be additive to that of lovastatin plus diet in patients with hypercholesterolaemia and coronary heart disease. [16] In obese women with polycystic ovary syndrome (who are frequently insulin resistant [17] and at risk of developing type 2 diabetes [18] ), metformin decreased fasting levels of insulin and the area under the curve of plasma insulin level versus time during an oral glucose tolerance test. In contrast, there was no significant change in the placebo group. [17] The potentially preventive effects of metformin in type 2 diabetes are summarised in table I. Decreases in total and LDL-cholesterol, free fatty acid, t-PA antigen and insulin levels may be obtained with metformin whatever the condition (hypertension, dyslipidaemia, visceral obesity or hyperglycaemia). Conversely, weight loss and accompanying decreases in PAI-1 levels should be expected only in obese patients and will be enhanced by concomitant dietary therapy. Effects on blood glucose levels and possibly blood pressure are seen in hyperglycaemic patients only.
Metformin responds to the pre-diabetic and premacroangiopathic anomalies that make up the insulin resistance syndrome through a variety of synergistic beneficial effects. Because of these properties and the good tolerability profile of the drug, metformin can be considered a first-line agent for the prevention of type 2 diabetes.
